Treatment persistence, hypoglycaemia and clinical outcomes in type 2 diabetes patients with dipeptidyl peptidase-4 inhibitors and sulphonylureas: A primary care database analysis

Diabetes, Obesity and Metabolism

Volumn 15, Issue 1, 2013, Pages 55-61

  Rathmann, W ^a   Kostev, K ^b   Gruenberger, J B ^c   Dworak, M ^c   Bader, G ^c   Giani, G ^a  

^a LEIBNIZ CENTER FOR DIABETES RESEARCH AT HEINRICH HEINE UNIVERSITY DÜSSELDORF   (Germany)

^b IQVIA   (United States)

^c NOVARTIS PHARMA AG   (Switzerland)

Author keywords

DPP 4 inhibitors; General practise; Hypoglycaemia; Sulphonylureas; Type 2 diabetes

Indexed keywords

DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLIBENCLAMIDE; GLIMEPIRIDE; METFORMIN; SULFONYLUREA DERIVATIVE;

ADULT; ADVERSE OUTCOME; AGE; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; DATA ANALYSIS; DISEASE COURSE; DISEASE DURATION; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; HEART FAILURE; HEART INFARCTION; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; HYPOGLYCEMIA; INTERNATIONAL CLASSIFICATION OF DISEASES; ISCHEMIC HEART DISEASE; KIDNEY DISEASE; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; MORBIDITY; NEUROPATHY; NON INSULIN DEPENDENT DIABETES MELLITUS; PERIPHERAL VASCULAR DISEASE; PRIMARY MEDICAL CARE; RETINOPATHY; SCORING SYSTEM; SEX DIFFERENCE; TREATMENT OUTCOME;

EID: 84871158616     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/j.1463-1326.2012.01674.x     Document Type: Article

References (24)

1. Nathan DM, Buse JB, Davidson MB et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2009; 32: 193-203.
2. Matthaei S, Bierwirth R, Fritsche A et al. Behandlung des Diabetes mellitus Type 2. Diabetologie 2011; 6: S131-136.
3. Dicker D. DPP-4 inhibitors: impact on glycemic control and cardiovascular risk factors. Diabetes Care 2011; 34(Suppl. 2): S276-278.
4. Richard KR, Shelburne JS, Kirk JK. Tolerability of dipeptidyl peptidase-4 inhibitors: a review. Clin Ther 2011; 33: 1609-1629.
5. Tiv M, Viel JF, Mauny F et al. Medication adherence in type 2 diabetes: The ENTRED Study 2007, a French Population-Based Study. PLoS One 2012; 7: e32412.
6. Karagiannis T, Paschos P, Paletas K, Matthews DR, Tsapas A. Dipeptidylpeptidase-4 inhibitors for treatment of type 2 diabetes mellitus in the clinical setting: systematic review and meta-analysis. BMJ 2012; 344: e1369.
7. Zhao Y, Campbell CR, Fonseca V, Shi L. Impact of hypoglycemia associated with antihyperglycemic medications on vascular risks in veterans with type 2 diabetes. Diabetes Care 2012; 35: 1126-1132.
8. Pantalone KM, Kattan MW, Yu C et al. The risk of overall mortality in patients with type 2 diabetes receiving different combinations of sulfonylureas and metformin: a retrospective analysis. Diabet Med 2012; 29: 1029-1035.
9. Pantalone KM, Kattan MW, Yu C et al. The risk of overall mortality in patients with type 2 diabetes receiving glipizide, glyburide, or glimepiride monotherapy: a retrospective analysis. Diabetes Care 2010; 33: 1224-1229.
10. Becher H, Kostev K, Schroder-Bernhardi D. Validity and representativeness of the disease analyzer patient database for use in pharmacoepidemiological and pharmacoeconomic studies. Int J Clin Pharmacol Ther 2009; 47: 617-626.
11. Greevy RA Jr, Huizinga MM, Roumie CL et al. Comparisons of persistence and durability among three oral antidiabetic therapies using electronic prescription-fill data: the impact of adherence requirements and stockpiling. Clin Pharmacol Ther 2011; 90: 813-819.
12. Quan H, Sundararajan V, Halfon P et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care 2005; 43: 1130-1139.
13. Cramer JA, Benedict A, Muszbek N, Keskinaslan A, Khan ZM. The significance of compliance and persistence in the treatment of diabetes, hypertension and dyslipidaemia: a review. Int J Clin Pract 2008; 62: 76-87.
14. Grégoire JP, Sirois C, Blanc G, Poirier P, Moisan J. Persistence patterns with oral antidiabetes drug treatment in newly treated patients - a population-based study. Value Health 2010; 13: 820-828.
15. Ligueros-Saylan M, Foley JE, Schweizer A, Couturier A, Kothny W. An assessment of adverse effects of vildagliptin versus comparators on the liver, the pancreas, the immune system, the skin and in patients with impaired renal function from a large pooled database of Phase II and III clinical trials. Diabetes Obes Metab 2010; 12: 495-509.
16. Stephens JM, Blak BT, Gold KF et al. Persistence patterns with oral hypoglycemic agents in type 2 diabetes. J Clin Outcomes Manag 2002; 9: 491-499.
17. Phung OJ, Scholle JM, Talwar M, Coleman CI. Effect of noninsulin antidiabetic drugs added to metformin therapy on glycemic control, weight gain, and hypoglycemia in type 2 diabetes. JAMA 2010; 303: 1410-1418.
18. Choudhary P, Amiel SA. Hypoglycaemia: current management and controversies. Postgrad Med J 2011; 87: 298-306.
19. Kahn SE, Haffner SM, Heise MA et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006; 355: 2427-2443.
20. Meinert CL, Knatterud GL, Prout TE, Klimt CR. A study of the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. II. Mortality results. Diabetes 1970; 19(Suppl): 789-830.
21. U.K. Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837-853.
22. Tzoulaki I, Molokhia M, Curcin V et al. Risk of cardiovascular disease and all cause mortality among patients with type 2 diabetes prescribed oral antidiabetes drugs: retrospective cohort study using UK general practice research base. Br Med J 2009; 339: b4731.
23. Rizzo M, Rizvi AA, Spinas GA, Rini GB, Berneis K. Glucose lowering and anti-atherogenic effects of incretin-based therapies: GLP1 analogues and DPP-4 inhibitors. Expert Opin Investig Drugs 2009; 18: 1495-1503.
24. Patil HR, Al Badarin FJ, Shami HA et al. Meta-Analysis of Effect of Dipeptidyl Peptidase-4 Inhibitors on Cardiovascular Risk in Type 2 Diabetes Mellitus. Am J Cardiol 2012 [Epub ahead of print].